GenScript proudly offers lipid nanoparticle (LNP) formulation services for mRNA and circular RNA drug research and development service.
LNPs have been proven to be an effective drug delivery system for RNA therapeutics which can be easily degraded in vivo. The lipid layer can fuse with the cell membrane, allowing the encapsulated RNA to enter the cell and exert its therapeutic effect. They also protect therapeutic agents from degradation and improve their bioavailability
LNPs are used in various applications, such as delivering RNA-based therapeutics or small molecules.
Variety of ionizable lipid formulation with high encapsulation efficiency
Proven in vitro delivery & expression efficiency
Tested for in vivo expression
via both I.M. and I.V.
Our integrated IVT RNA manufacturing workflow streamlines production from gene synthesis to LNP packaging.
| Item | Test Method | Specification | RUO Standard QC | RUO Upgrade QC |
|---|---|---|---|---|
| Appearance | Visual Inspect | Clear and free of foreign particles | ||
| Final Concentration | RiboGreen assay | 0.05~ 0.4 mg/mL | ||
| Encapsulation Efficiency | RiboGreen assay | > 80% | ||
| Encapsulated RNA Integrity | Bioanalyzer | > 75% | ||
| Particle size | Dynamic light scattering | POI ±20 nm , 65 ~ 150 nm | ||
| Poly Dispersity Index | Dynamic light scattering | < 0.28 | ||
| Zeta Potential | Zetasizer by dynamic light scattering | ± 15.0 mV | ||
| PH | pH paper | 7.4 ± 0.5 | ||
| Endotoxin | Quantitative | <0.5 EU/ml | ||
| Bioburden | Direct inoculation | No Growth after 48hrs |
eSpCas9 mRNA and TRAC sgRNA were mixed at 1:1 weight ratio and delivered through LP01-LNP formulation (2.4 ug of RNA/LNP) or lipofectamine to HEK293T cells, then cell were lysed at day 3 and 5 for PCR and Sanger sequencing. Results showed 97% editing efficiency with LNP compared to 61% with lipofectamine.
Transfection efficiency was compared by delivering eGFP mRNA (100% N1-methyl-pseU modified, GenScript) into Jurkat and THP-1 immune cells using SM102-LNP (GenScript), Lipofectamine™ MessengerMAX™ (ThermoFisher Scientific) and TransIT® (Mirus). 100ng of mRNA were transfected into cells in 24 well plates. Starvation medium (OptiMEM) was used for lipofectamine and TransIT per the manufacturer’s instruction, and complete medium was used for LNP. The expression of eGFP was measured by flow cytometry after 48 hours.
In vivo delivery efficiency of four different LNP formulations was compared by delivering Fluc mRNA (100% N1-methyl-pseU modified, GenScript) into Balb-C mice via IM injection at a dose of 0.25mg/kg. The expression of Fluc mRNA was measured by whole-body bioluminescence imaging.
Fluc mRNA delivered by MC3-LNP showed the highest expression level after 8 and 48 hours by imaging at both Dorsal and Ventral pose of mice. To evaluate the biodistribution profile of different formulations, the heart, liver, lung, spleen, kidney, and brain of the mice were collected and imaged after 48 hours, MC3 -LNP formulation showed the strongest liver accumulation compared to others after 48 hours.
In vivo delivery efficiency of two different LNP formulations was compared by delivering Fluc mRNA (100% N1-methyl-pseU modified, GenScript) into Balb-C mice via IV injection at a dose of 0.3mg/kg. The expression of Fluc mRNA was measured by whole-body bioluminescence imaging.
In imaging analysis, Fluc-mRNA delivered by SM102-LNP showed higher expression efficiency than MC3 after 8 and 48 hours. To evaluate the biodistribution profile of different formulations, heart, liver, lung, spleen, kidney, and brain of the mice were collected and imaged after 48 hours, SM102 -LNP showed stronger liver accumulation compared to MC3-LNP after 48 hours. MC3-LNP showed stronger spleen accumulation after 48 hrs. Neither formulation caused significant body weight loss during the experiment period for 3 days.
What is an LNP?
Lipid nanoparticles (LNPs) are natural or synthetic molecules that can self-assemble into a spherical structure. LNPs are typically composed of lipid layer, which forms a shell around an inner compartment that can be used to deliver drugs or other therapeutic agents. LNPs have become increasingly popular as a drug delivery system due to their ability to protect therapeutic agents from degradation and improve their bioavailability. They can also be designed to target specific cells or tissues, allowing for more precise delivery of drugs. LNPs have been used in various applications, including the delivery of RNA-based therapeutics such as mRNA vaccines. The lipid layer of LNPs can fuse with the cell membrane, allowing the encapsulated RNA to enter the cell and exert its therapeutic effect. LNPs have also been investigated as a potential delivery system for other types of drugs, including small molecules and proteins.
mRNA LNP in vitro Cell Transfection - LNP transfection is as easy as 1, 2, 3
Case studies demonstrating encapsulation and delivery efficiency of GenScript’s new LNP formulations in cell models, and mouse models via both IM and IV.
Free Download
High-quality custom mRNA production via our proprietary IVT RNA manufacturing workflow.
Learn More
Our off-the-shelf mRNA is optimized with 5’ cap and polyA tails that is ready to use for your research needs
Learn More
Circular RNA offers improved stability and longer expression duration.
Learn More
High quality linearized DNA plasmid for better quality and consistency of your mRNA production
Learn More
